{
    "id": 2807,
    "fullName": "MSH2 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "MSH2 loss indicates loss of the MSH2 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4436,
        "geneSymbol": "MSH2",
        "terms": [
            "MSH2",
            "COCA1",
            "FCC1",
            "hMSH2",
            "HNPCC",
            "HNPCC1",
            "LCFS2"
        ]
    },
    "variant": "loss",
    "createDate": "12/22/2014",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1532,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells deficient in MSH2 had increased sensitivity to Cytosar-U (cytarabine) in culture (PMID: 23361057).",
            "molecularProfile": {
                "id": 2640,
                "profileName": "MSH2 loss"
            },
            "therapy": {
                "id": 712,
                "therapyName": "Cytarabine",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1451,
                    "pubMedId": 23361057,
                    "title": "Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23361057"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "Preclinical shRNA mediated-inhibition of POLB in human endometrial carcinoma cells with MSH2 loss resulted in synthetic lethality, suggesting POLB may be a promising therapeutic target for MSH2 deficient cancer cells (PMID: 20227038).",
            "molecularProfile": {
                "id": 2640,
                "profileName": "MSH2 loss"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3078,
                    "pubMedId": 20227038,
                    "title": "DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20227038"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2640,
            "profileName": "MSH2 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}